Talley Rw

414 citations
24 papers · 332 indexed · h-index 8

Impact in

    • Cancer Treatment and Pharmacology
    • Metal complexes synthesis and properties
    • Lung Cancer Research Studies
    • Lymphoma Diagnosis and Treatment
    • Chemotherapy-induced organ toxicity mitigation

Papers in

    • Cancer Treatment and Pharmacology 4
    • Colorectal Cancer Treatments and Studies 3
    • Lung Cancer Research Studies 2
    • Cancer and Skin Lesions 2
Journals
PubMed (24 papers)
Partner nations
United States

In The Last Decade

Talley Rw

22 papers receiving 292 citations

Peers

Talley Rw
Comparison fields: 5 of 65
  • Oncology 172
  • Pathology and Forensic Medicine 68
  • Pulmonary and Respiratory Medicine 86
  • Neurology 31
  • Cardiology and Cardiovascular Medicine 46
Replace Larry L. Schenken with:
Larry L. Schenken United States
G Martz Switzerland
Comis Rl United States
Schutt Aj United States
Eagan Rt United States
Bohumil A. Samal United States
Brian M.J. Cantwell United Kingdom
M. Varini Switzerland
Chabner Ba United States
Jean‐Nicolas Munck France
Talley Rw relative to Larry L. Schenken United States Larry L. Schenken's profile →
Citations per field
00.5×1.5×
Larry L. Schenken · 1×
Citations per year

Countries citing papers authored by Talley Rw

Since Specialization
Citations

This map shows the geographic impact of Talley Rw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Talley Rw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Talley Rw more than expected).

Fields of papers citing papers by Talley Rw

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Talley Rw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Talley Rw. The network helps show where Talley Rw may publish in the future.

Co-authorship network

The 18 scholars most cited alongside Talley Rw, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Talley Rw Line = papers co-authored together Talley Rw links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1
Phase II trial of amsacrine in metastatic or locally recurrent squamous cell carcinoma from head and neck primaries: a Southwest Oncology Group study.
19842
2
Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group Study.
19825
3
Phase II study of AMSA in lung cancer.
198117
4
Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study.
198054
5
Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study.
198019
6
Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma.
197811
7
Porfiromycin in the management of epidermoid and transitional cell cancer: a phase II study.
19764
8
Guanazole (NSC-1895)--a phase I clinical study.
19763
9
Treatment of adenocarcinoma with combinations of cyclopjosphamide (NSC-26271), vincristine (NSC-67574), and 5-fluorouracil (NSC-19893).
19753
10
Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)--phase I clinical study.
197482
11
Response of advanced breast cancer to two dosage regiments of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
19732
12
Clinical evaluation of 1,3-bis(2-chloroethyl)-nitrosourea (BCNU; NSC-409962) with fluoxymesterone (NSC-12165) in the treatment of solid tumors.
19733
13
Proceedings: Chemotherapy of soft-tissue sarcomas.
19722
14
Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388).
197058
15
Investigational and practical chemotherapy of solid tumors.
19702
16
The clinical use of fluorine18 in bone scanning.
19695
17
Preliminary trials with combination therapy of cyclophosphamide (NSC-26271), vincristine (NSC-67574), and 5-fluorouracil (NSC-19893).
19687
18
Critical analysis of the control of malignant effusions with radioisotopes.
196818
19
Clinical pharmacologic study of kethoxal bis(thiosemicarbazone) [NSC-82116] in advanced cancer.
19671
20
Chemotherapy of advanced ovarian cancer.
19612

About Talley Rw

Talley Rw is a scholar working on Oncology, Dermatology, Cancer Research, Pharmaceutical Science and Pulmonary and Respiratory Medicine, having authored 24 papers that have together received 332 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Lung Cancer Treatments and Mutations (3 papers), Beetle Biology and Toxicology Studies (2 papers), Cancer and Skin Lesions (2 papers), Lung Cancer Research Studies (2 papers), Cancer therapeutics and mechanisms (2 papers) and Click Chemistry and Applications (1 paper). The work is most often cited by research in Oncology (172 citations), Pathology and Forensic Medicine (68 citations), Pulmonary and Respiratory Medicine (86 citations), Neurology (31 citations) and Cardiology and Cardiovascular Medicine (46 citations). Talley Rw has collaborated with scholars based in United States. Frequent co-authors include R I Fisher, C. W. Groppe, Tate Thigpen, Baker Lh, Coltman Ca, Jones Se, Emil Frei, Bethan McDonald, Glenn Cummings and Mary M. Lane. Their work appears in journals such as PubMed.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026